NCT00769041View on ClinicalTrials.gov

A Thorough EKG Safety Study of TA-1790 (Avanafil)

PHASE1CompletedINTERVENTIONAL

Enrollment

57

Participants

Timeline

Start Date

October 31, 2008

Primary Completion Date

January 31, 2009

Study Completion Date

January 31, 2009

Conditions

Erectile Dysfunction

Interventions

DRUG

moxifloxacin

400mg

DRUG

avanafil

100mg single dose

DRUG

avanafil

800mg single dose

DRUG

sugar pill

single dose

Trial Locations (1)

53704

Covance Phase 1 Clinical Unit, Madison

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Covance

INDUSTRY

lead

VIVUS LLC

INDUSTRY

NCT00769041 - A Thorough EKG Safety Study of TA-1790 (Avanafil) | Biotech Hunter | Biotech Hunter